Toxicity of prolonged treatment with eribulin (E) in metastatic breast cancer (MBC) patients: Results of the EXTER study.
Francisco Ayala(Hospital General Universitario Morales Meseguer), Jesús Florián Gericó(Centro de Salud Casa del Barco), José Á. García-Sáenz(Hospital Clínico San Carlos), Ignacio Delgado(Universitat Autònoma de Barcelona), Margarita Rodriguez Moral, Pedro Sánchez‐Rovira(Complejo Hospitalario de Jaén), Coralia Bueno(Hospital Universitario Fundación Alcorcón), E. Calvo(Hospital de Basurto), Noelia Martínez-Jáñez(Instituto Cajal), F. Carabantes(Hospital Doctor José Molina Orosa), R. Pérez-Carrión(Hospital Universitario Quirónsalud Madrid), Juan Lao(Hospital Universitario Miguel Servet), M. Quezada Feijoo(Hospital General de La Rioja), Pedro Salinas(Hospital La Luz), Amalia Gómez, Valero Pedro Jimenez, María Valero Arbizu(Hospital Quirónsalud Sagrado Corazón)
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268